Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood pressure drug clear ICU brain fog?

NCT ID NCT04742673

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving intravenous guanfacine to critically ill patients with delirium in the ICU could improve their brain function. 46 adults on breathing machines or for shock were randomly assigned to receive guanfacine or a placebo. Researchers measured days without delirium or coma, time off the ventilator, and cognitive test scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Guanfacine (intravenous)
What this could lead to
If it works, this could point toward a treatment to reduce delirium and improve thinking in critically ill patients.
What could go wrong
This is a small, early-phase proof-of-concept study with only 46 participants. Results may not apply to all ICU patients, and the drug may cause side effects like low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

46 people

The number who actually took part.

Started

May 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. adult patients (≥ 18 years old) 2. requiring admission to an ICU 3. for treatment of respiratory failure (e.g., mechanical ventilation, non-invasive positive pressure ventilation \[NIPPV\], Extracorporeal Membrane Oxygenation \[ECMO\], optiflow) and/or for treatment of shock (e.g., vasopressors, ECMO, intra-aortic balloon pump \[IABP\]). Exclusion Criteria: 1. allergic to guanfacine, clonidine, or dexmedetomidine 2. on home antipsychotics who, therefore, require continuing antipsychotic administration in the hospital 3. present history of 2nd or 3rd degree heart block, or persistent bradycardia \< 50 beats/minute that requires intervention (e.g., atropine, glycopyrrolate). If patient has a pacemaker for bradyarrythmias, then patient does not meet this exclusion criterion and may be enrolled. 4. co-enrolled in another interventional trial examining similar outcomes or in a study that does not allow co-enrollment 5. expected death within 24 hours of enrollment or lack of commitment to aggressive treatment by family or the medical team (e.g., likely withdrawal of life support measures within 24 hours of screening) 6. acute or subacute neurologic deficit that is expected to make the patient incapable of living independently after hospital discharge due to cognitive deficits (e.g., stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, cerebral edema). 7. dementia or other chronic neurologic disease or disorder that makes the patient incapable of living independently at baseline 8. active substance abuse, psychotic disorder, or homelessness without a secondary contact person (which would make long-term follow-up difficult) 9. blindness or deafness (which would prevent assessment of the study's outcomes) 10. pregnancy or breastfeeding 11. prisoner 12. inability to start informed consent process within 72 hours from the time that all inclusion criteria were met 13. Cardiac surgery within the current hospitalization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Critical Illness delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.